Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity

Virologica Sinica

Volumn 28, Issue 3, 2013, Pages 167-173

  Naderi, Malihe ^a   Saeedi, Atefeh ^b   Moradi, Abdolvahab ^c   Kleshadi, Mishar ^c   Zolfaghari, Mohammad Reza ^a   Gorji, Ali ^d,e   Ghaemi, Amir ^c,d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Shefa Neuroscience Research Centre   (Iran)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

DNA vaccine; Hepatitis C virus (HCV); Interleukin 12; NS3

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEPATITIS C VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 4; NONSTRUCTURAL PROTEIN 3; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NS3 GENE; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; VACCINATION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; VACCINES, DNA; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EUKARYOTA; HEPATITIS C VIRUS; MURINAE; MUS;

EID: 84879222681     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3291-z     Document Type: Article

References (44)

1. Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, and Sallberg M. 2005. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocyte by DNA vaccine-primed cytotoxic T lymphocyte. J Infec Dis, 192(12): 2112-2116.
2. Ahlen G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, and Sällberg M. 2007. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol, 179(7): 4741-4753.
3. Andre S, Seed B, Eberle J, Schraut W, Bültmann A, and Haas J. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol, 72(2): 1497-1503.
4. Arribillaga L, de Cerio A L, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borrás-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, and Lasarte J J. 2002. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus. Vaccine, 21: 202-210.
5. Bartenschlager R, Ahlborn-Laake L, Mous J, and Jacobsen H. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol, 67: 3835-3844.
6. Bocher W O, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle P R, F Löhr H, and Reisner Y. 2001. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol, 31: 2071-2079.
7. De Francesco R, Tomei L, Altamura S, Summa V, and Migliaccio G. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA dependent RNA polymerase. J Antiviral Res, 58(1):1-16.
8. Encke J, zuPutlitz J, Geissler M, and R Wands J. 1998. Genetic Immunization generates cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model. J Immunol, 1(61): 4917-4923.
9. Feltquate D M, Heaney S, Webster R G, and Robinson H L. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 158: 2278-2284.
10. Foy E, Li K, Sumpter R, Loo Y M, Johnson C L, Wang C, Fish P M, Yoneyama M, Fujita T, Lemon S M, and Gale M Jr. 2004. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102(8): 2986-2991.
11. Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, and Sällberg M. 2004. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. J Gene Ther, 11(6): 522-533.
12. Frick D N. 2007. The hepatitis C virus NS3 protein: a model RNA helicase andpotential drug target. Curr Issues Mol Biol, 9(1):1-20.
13. 4+ Th1 cell responses in vivo. Vaccine, 24: 5491-5497.
14. Geissler M, Gesien A, Tokushige K, and Wands J R. 1997. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids. J Immunol, 158:1231-1237.
15. Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi M, and Ebtekar E. 2007. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. J Comp immunol microbiol Infect Dis, 30(4):197-210.
16. Ghaemi A, Soleimanjahi H, Gill P, Zuhair H, Razeghi M, Jahromi S, and Roohvand F. 2010. Recombinant λ-phage nanobioparticles for tumor therapy in mice models. J Genet Vaccines Ther, 8(3): 1-7.
17. Ghaemi A, Soleimanjahi H, Gill P, Zuhair M H, Razeghi S, Fazeli M, and Razavinikoo S M H. 2009. Protection of Mice by a -Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16. J Intervirol, 54:105-112.
18. Gherardi M M, Ramirez J C, and Esteban M. 2000. Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost VaccineRegimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J Virol, 74: 6278-6286.
19. Guermonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S. 2002. Antigen presentation and T cell stimulation by dendritic cells. J Annu Rev Immunol, 20: 621-667.
20. Gurunathan S, Klinman D M, and Seder R A. 2000. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol, 18: 927-974.
21. Ha S J, Jeon B Y, Kim S C, Kim D J, Song M K, Sung Y C, and Cho S N. 2003. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis. J Gene Ther, 10: 1543.
22. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, and Shimotohno K. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol, 67: 4665-4675.
23. Jiao X, Wang R Y, Feng Z, Hu G, Alter H J, and W-K Shih J. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. 2004. J Viral Hepatol, 11(1):18-26.
24. Kim J J, Ayyavoo V, Bagarazzi M L, Chattergoon M A, Dang K, Wang B, Boyer J D, and Weiner D B. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol, 158: 816-826.
25. Kieper W C, Tan J T, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, and Surh C D. 2002. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med, 195: 1533.
26. 8+ T cell homeostatic expansion. J Immunol, 166: 5515.
27. Koff R S. 2003. Hepatitis vaccines: recent advances. Int J Parasitol, 33: 517-523.
28. Lanford R E, Guerra B, Chavez D, Bigger C, Brasky K M, Wang X H, Ray S C, and Thomas D L. 2004. Cross-genotype immunity to hepatitis C virus. J Virol, 78(3):1575-1581.
29. Lang K A, Yan J, Draghia-Akli R, Khan A, and Weiner D B. 2008. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine, 26(49): 6225-6231.
30. Lauer G M, and Walker B D. 2001. Hepatitis C virus infection. N Engl J Med, 345: 41-52.
31. Martin T. 1999. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther, 10(5):759-768.
32. Nichols W W. 1995. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci, 772: 30-39.
33. + T helper cells in chronic HCV infection. J Hepatol, 41(5): 1019-1102.
34. Pang P S, Jankowsky E, Planet P J, and Pyle A M. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J, 21: 1168-1176.
35. Pawlotsky J M. 2009. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol, 6(7): 383-385.
36. Schmidt C S, and Mescher M F. 1999. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD81 T cells in vivo. J Immunol, 163: 2561.
37. Scott P, and Trinchieri G. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin J Immunol, 9: 285-291.
38. 4+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus-2 Challenge. J Immunol, 162: 2912-2921.
39. Shan M M, Liu K Z, Fang H L, and Chen Z. 2002. DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigen. HBPD INT, 1(4): 553-557.
40. Tokushige K, Wakita T, Pachuk C, Moradpour D, Wener D B, Zurawski J R V R, and Wands J R. 1996. Expression and Immune Response to Hepatitis C Virus Core DNA-Based Vaccine Constructs. J Hepatol, 24:14-20.
41. Weck K. 2005. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn, 5(4): 507-520.
42. Weiner A J, Paliard X, Selby M J, Medina-Selby A, Coit D, Nguyen S, Kansopon Joe, L Arian Ch, Ng Ph, Tucker Jeffery, Lee Ch-T, K Polakos N, Han J, Wong Sh, Lu H-H, Rosenberg S, M Brasky K, Chien D, Kuo G, and Houghton M. 2001. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol, 75(15): 7142-7148.
43. Xiang Z, and Ertl H C. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. J Immunity, 2: 129-135.
44. Yang S H, Lee C G, Park S H, Im S J, Kim Y M, Son J M, Wang J S, Yoon S K, Song M K, Ambrozaitis A, Kharchenko N, Yun Y D, Kim C M, Kim C Y, Lee S H, Kim B M, Kim W B, and Sung Y C. 2006. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. J Gene Ther, 13(14): 1110-1117.